β-lactam antibiotic concentrations during continuous renal replacement therapy

Critical Care

Volumn 18, Issue 3, 2014, Pages

  Beumier, Marjorie ^a   Casu, Giuseppe S ^a   Hites, Maya ^a   Seyler, Lucie ^a   Cotton, Frederic ^a   Vincent, Jean Louis ^a   Jacobs, Frédérique ^a   Taccone, Fabio S ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTAZIDIME; CREATININE; HYPERTENSIVE FACTOR; IMMUNOSUPPRESSIVE AGENT; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAM;

ABDOMINAL INFECTION; ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; CLINICAL ARTICLE; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; ENTEROBACTERIACEAE INFECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LUNG INFECTION; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; OXYGEN THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; BLOOD; DRUG EFFECTS; INTENSIVE CARE UNIT; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PROCEDURES; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEPSIS; TRENDS;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SEPSIS;

EID: 84903188925     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13886     Document Type: Article

References (37)

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II, Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319, Group of Investigators.
2. Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26:S64-S74. 10.1007/s001340051121, 10786961.
3. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34:1589-1596. 10.1097/01.CCM.0000217961.75225.E9, 16625125.
4. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228. 10.1007/s00134-012-2769-8, 23361625, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup.
5. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474. 10.1378/chest.115.2.462, 10027448.
6. Zaragoza R, Artero A, Camarena JJ, Sancho S, González R, Nogueira JM. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9:412-418. 10.1046/j.1469-0691.2003.00656.x, 12848754.
7. Pinder M, Bellomo R, Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002, 30:134-144.
8. Adnan S, Li JX, Wallis SC, Rudd M, Jarrett P, Paterson DL, Lipman J, Udy AA, Roberts JA. Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. Int J Antimicrob Agents 2013, 42:90-93. 10.1016/j.ijantimicag.2013.02.023, 23590897.
9. Heinemeyer G, Link J, Weber W, Meschede V, Roots I. Clearance of ceftriaxone in critical care patients with acute renal failure. Intensive Care Med 1990, 16:448-453. 10.1007/BF01711224, 2269714.
10. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005, 41:1159-1166. 10.1086/444500, 16163635.
11. Matzke GR, Frye RF, Joy MS, Palevsky PM. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000, 44:1639-1644. 10.1128/AAC.44.6.1639-1644.2000, 89925, 10817721.
12. Mueller SC, Majcher-Peszynska J, Hickstein H, Francke A, Pertschy A, Schulz M, Mundkowski R, Drewelow B. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002, 46:1557-1560. 10.1128/AAC.46.5.1557-1560.2002, 127124, 11959598.
13. Valtonen M, Tiula E, Backman JT, Neuvonen PJ. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000, 45:701-704. 10.1093/jac/45.5.701, 10797097.
14. Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012, 40:1523-1528. 10.1097/CCM.0b013e318241e553, 22511133, RENAL Replacement Therapy Study Investigators.
15. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011, 15:R137. 10.1186/cc10257, 3219006, 21649882.
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. International Sepsis Definitions Conference. Intensive Care Med 2003, 29:530-538. 10.1007/s00134-003-1662-x, 12664219.
17. van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997, 23:873-877. 10.1007/s001340050424, 9310805.
18. Malone RS, Fish DN, Abraham E, Teitelbaum I. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45:3148-3155. 10.1128/AAC.45.11.3148-3155.2001, 90796, 11600370.
19. Wolff F, Deprez G, Seyler L, Taccone F, Hites M, Gulbis B, Vincent JL, Jacobs F, Cotton F. Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients. Talanta 2013, 103:153-160.
20. Clinical Breakpoint for Gram Negative Bacteria. [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/%20Breakpoint_tables/Breakpoint_table_v_3.1.pdf] (Last accessed 14 October 2013).
21. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009, 37:2268-2282. 10.1097/CCM.0b013e3181aab3d0, 19487930.
22. Ververs TF, van Dijk A, Vinks SA, Blankestijn PJ, Savelkoul JF, Meulenbelt J, Boereboom FT. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000, 28:3412-3416. 10.1097/00003246-200010000-00006, 11057794.
23. Krueger WA, Schroeder TH, Hutchison M, Hoffmann E, Dieterich HJ, Heininger A, Erley C, Wehrle A, Unertl K. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998, 42:2421-2424. 105844, 9736574.
24. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001, 48:881-885. 10.1093/jac/48.6.881, 11733473.
25. Gangireddy VGR, Mitchell LC, Coleman T. Cefepime neurotoxicity despite renal adjusted dosing. Scand J Infect Dis 2011, 43:827-829. 10.3109/00365548.2011.581308, 21604923.
26. Huang WT, Hsu YJ, Chu PL, Lin SH. Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure. Infection 2009, 37:374-376. 10.1007/s15010-009-8373-3, 19499182.
27. Maganti R, Jolin D, Rishi D, Biswas A. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 2006, 8:312-314. 10.1016/j.yebeh.2005.09.010, 16278098.
28. Klion AD, Kallsen J, Cowl CT, Nauseef WM. Ceftazidime-related nonconvulsive status epilepticus. Arch Int Med 1994, 154:586-589.
29. Smith NL, Freebairn RC, Park MA, Wallis SC, Roberts JA, Lipman J. Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Critical Care Resusc 2012, 14:312-315.
30. Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller MD, Berger MM, Bolay S, Décosterd LA, Bugnon D, Moreillon P. Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14:R51. 10.1186/cc8941, 2887166, 20359352.
31. Covajes C, Scolletta S, Penaccini L, Ocampos-Martinez E, Abdelhadii A, Beumier M, Jacobs F, de Backer D, Vincent JL, Taccone FS. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Intern J Antimicrob Agents 2013, 41:261-266.
32. Arzuaga A, Isla A, Gascón AR, Maynar J, Corral E, Pedraz JL. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif 2006, 24:347-354. 10.1159/000092921, 16645266.
33. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351. 10.1016/j.ijantimicag.2007.12.009, 18313273.
34. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002, 50:425-428. 10.1093/jac/dkf130, 12205070.
35. Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014, Epub ahead of print.
36. Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy 2010, 30:453-462. 10.1592/phco.30.5.453, 20411997.
37. Goncalves-Pereira J, Paiva JA. Dose modulation: a new concept of antibiotic therapy in the critically ill patient?. J Crit Care 2013, 28:341-346. 10.1016/j.jcrc.2012.11.018, 23337485.